Drug intelligence / Profile preview

INT-777

Development stage: Preclinical
Lead developer: Alfasigma
Modality: Small Molecules
Administration: Intranasal, Intraperitoneal, Oral, Serosal

Overview

INT-777 is a small molecule TGR5 agonist developed by Intercept Pharmaceuticals. It is being investigated for the treatment of chronic fibrotic and metabolic diseases, including type 2 diabetes and related metabolic disorders. Intercept Pharmaceuticals entered into a research agreement with Servier for its TGR5 program, which includes INT-777. Under this agreement, Servier is responsible for global development, regulatory approval, and commercialization of any selected lead candidate, excluding the U.S. and Japan, where Intercept retains all rights. The development of INT-777 was supported by a Series B financing round from Genextra, aimed at advancing Intercept's clinical programs for its lead compounds.

Targets

GPBAR1

Beyond the preview

Go deeper on INT-777.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INT-777.

Explore the full profile